Author
Bahram Hassanpourfard
-
FDA approves GSK and Ionis hepatitis B drug offering potential functional cure
The FDA approved bepirovirsen, a first of its kind antisense injection for chronic hepatitis B from GSK and Ionis, as dealmaking led the rest of the week’s coverage.
-
Pfizer, Roche and AstraZeneca lead a week of drug discovery deals
Pfizer, Roche and AstraZeneca each struck discovery deals reported at $500m or more, as regulators in the UK, US and Europe signalled changes in how they weigh evidence.
-
AI puts the ultrasound probe in more hands as histotripsy reaches a $3.75bn valuation
AI guidance is putting the ultrasound probe in more hands, the major vendors have refreshed their ranges and histotripsy has reached a $3.75bn valuation.
-
NHS prescribing bill set to run about £460m above inflation in 2026, driven by GLP-1s
England’s NHS prescribing bill is on course to finish 2026 well ahead of inflation.
-
FDA approves first heart valve designed to grow with children
The FDA approved the Autus Size-Adjustable Valve, a surgically implanted pulmonary heart valve for paediatric patients with congenital pulmonary valve disease, which it describes as the first heart valve designed to grow with children.
-
FDA approves AbbVie’s first-in-class Parkinson’s pill as pharma deal-making accelerates
The FDA approved AbbVie’s tavapadon, branded Juvmo, for adults with Parkinson’s disease, as deal-making dominated the rest of the week.
-
Apotek Analytics welcomes Dr Oliver Hulson to our advisory board
Dr Oliver Hulson, Consultant Radiologist at Leeds Teaching Hospitals NHS Trust, joins the Apotek Analytics advisory board.